Roach Amy, Emerson Dominic, Megna Dominick, Cole Robert, Catarino Pedro, Salabat Reza, Ramzy Danny, Moriguchi Jamie, Kobashigawa Jon, Trento Alfredo, Chikwe Joanna, Esmailian Fardad
From the Department of Cardiac Surgery, Cedars-Sinai Medical Center.
Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California.
ASAIO J. 2023 Jan 1;69(1):76-81. doi: 10.1097/MAT.0000000000001721. Epub 2022 May 10.
In patients with severe cardiogenic shock, temporary mechanical circulatory support has become a viable strategy to bridge patients to heart transplantation. However, end-stage heart failure is often associated with progressive organ dysfunction of the liver or kidney. This can require a dual organ transplant for definitive management (combined heart-liver [HL] or heart-kidney [HK] transplantation). We evaluated temporary mechanical support to bridge patients to HL or HK transplant at a single, high-volume center. All patients who underwent Impella 5.0 placement from January 2014 to October 2018 were identified. From this dataset, patients who underwent placement as a bridge to dual organ transplant were selected, as were those who underwent Impella as a bridge to isolated heart transplant. Over the 5 years of evaluation, 104 patients underwent Impella 5.0 placement. Of these, 14.3% (n = 15) were identified as potential dual organ recipients (11 HK, 4 HL). In total, 80% (12/15) successfully underwent dual organ transplant (8 HK, 4 HL), with a 1-year survival of 100% in both transplanted groups. Among patients undergoing Impella 5.0 placement as a bridge to isolated heart transplant (n = 33), 78.8% (26) were successfully bridged, and 1-year survival was 92% after transplantation. Impella 5.0 is a viable bridge to dual organ transplantation and should be considered as a management strategy in these complex patients at experienced institutions.
在严重心源性休克患者中,临时机械循环支持已成为将患者过渡到心脏移植的可行策略。然而,终末期心力衰竭常伴有肝脏或肾脏的进行性器官功能障碍。这可能需要进行双器官移植以进行确定性治疗(心脏 - 肝脏联合移植[HL]或心脏 - 肾脏联合移植[HK])。我们在一个高容量的单一中心评估了使用临时机械支持将患者过渡到HL或HK移植的情况。确定了2014年1月至2018年10月期间所有接受Impella 5.0植入的患者。从该数据集中,选择了作为双器官移植过渡而接受植入的患者,以及作为孤立心脏移植过渡而接受Impella植入的患者。在5年的评估期内,104例患者接受了Impella 5.0植入。其中,14.3%(n = 15)被确定为潜在的双器官接受者(11例HK,4例HL)。总体而言,80%(12/15)成功接受了双器官移植(8例HK,4例HL),两个移植组的1年生存率均为100%。在作为孤立心脏移植过渡而接受Impella 5.0植入的患者中(n = 33),78.8%(26例)成功过渡,移植后1年生存率为92%。Impella 5.0是双器官移植的可行过渡方式,在有经验的机构中应将其视为这些复杂患者的一种治疗策略。